T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT

類似資料

• Genetic variations in T-cell activation and effector pathways modulate alloimmune responses after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies
  著者:: Xiao, Haowen, 等
  出版事項: (2012)
• Co-transplantation of mesenchymal stem cells makes haploidentical HSCT a potential comparable therapy with matched sibling donor HSCT for patients with severe aplastic anemia
  著者:: Liu, Zenghui, 等
  出版事項: (2020)
• Myeloablative vs reduced intensity T-cell–replete haploidentical transplantation for hematologic malignancy
  著者:: Solomon, Scott R., 等
  出版事項: (2019)
• The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis
  著者:: Lorentino, Francesca, 等
  出版事項: (2017)
• Immune tolerance induction by nonmyeloablative haploidentical HSCT combining T-cell depletion and posttransplant cyclophosphamide
  著者:: Aversa, Franco, 等
  出版事項: (2017)